3-苯基异恶唑 | 1006-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苯基异恶唑
• 中文别名: 3-苯基异噁唑
• 英文名称: 3-phenylisoxazole
• 英文别名: 3-phenyl-1,2-oxazole
• CAS: 1006-65-1
• 化学式: C₉H₇NO
• 分子量: 145.161
• InChiKey: ZBRDJMFLJXFIGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  110-111 °C
• 沸点：
  128 °C(Press: 16 Torr)
• 密度：
  1.1399 g/cm3(Temp: 18.6 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 储存条件：
  室温下密封保存，并确保环境干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Phenyl-1,2-oxazole
Synonyms: 3-Phenylisoxazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Phenyl-1,2-oxazole
CAS number: 1006-65-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7NO
Molecular weight: 145.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-苯基异恶唑 在 [Ir(COD)(MesMesIm)PBn₃]PF₆ 、 氘 作用下， 以 二氯甲烷 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 1.0h， 以100%的产率得到3-(2,6-Dideuteriophenyl)-1,2-oxazole
  参考文献：
  名称：

  铱（I）NHC /膦催化剂在与药物相关的杂环氢同位素交换过程中的扩展适用性

  摘要：

  评估了在N-杂环氘代中[[COD）Ir（IMes）（PR 3）] PF 6类型的新兴C–H活化催化剂的评估。底物范围，竞争实验和药物类型分子的标记显示，与本系列中的其他可用配合物相比，PR 3 PPh 3提供了更广泛适用和更有效的催化剂体系。

  DOI：

  10.1016/j.tet.2015.02.029
• 作为产物：
  描述：

  苯甲腈 N-氧化物 在 正丁基锂 、 sodium methylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-苯基异恶唑
  参考文献：
  名称：

  取代的苄腈氧化物与乙醛的烯醇酸根离子反应合成3-芳基-4,5-二氢-5-羟基-1,2-恶唑

  摘要：

  通过使取代的苄腈氧化物与乙醛的烯醇盐离子反应（由正丁基锂存在下已知的THF环还原定量地产生），可以生成许多3-芳基-4,5-二氢-5-羟基-1，2-高产率地分离了恶唑（以前未知，或者在两种情况下，仅通过不同的方法合成）。用一些常见的碱处理此类羟基异恶唑啉可使其以高收率转化成相应的异恶唑。

  DOI：

  10.1016/s0040-4020(01)86800-9

文献信息

• Catalyst Control in Positional-Selective C–H Alkenylation of Isoxazoles and a Ruthenium-Mediated Assembly of Trisubstituted Pyrroles
  作者：Pravin Kumar、Manmohan Kapur

  DOI：10.1021/acs.orglett.9b00446

  日期：2019.4.5

  determining the positional selectivity in C–H alkenylation of isoxazoles. A cationic rhodium-mediated, strong-directing group promotes C(sp2)-H activation at the proximal aryl ring whereas, the palladium-mediated electrophilic metallation leads to the C(sp2)-H activation at the distal position of the directing group. Synthetic elaboration of this C–H alkenylation product via ruthenium and copper co-catalysis

  在确定异恶唑的CH链烯基化反应中的位置选择性方面，证明了高水平的催化剂控制能力。阳离子铑介导的强方向性基团在近端芳基环处促进C（sp 2）-H活化，而钯介导的亲电金属化作用则在该方向的远端位置导致C（sp 2）-H活化团体。通过钌和铜的共催化合成这种C–H链烯基化产物，可得到一种高效的方法，用于组装密集取代的吡咯。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2016046530A1

  公开（公告）日：2016-03-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C端水解酶L1（UCHL1）。本发明进一步涉及在癌症和其他适应症治疗中使用DUB抑制剂。本发明的化合物包括具有式（I）或其药用可接受盐的化合物，其中R1至R8如本文所定义。
• Unusual Reactivity of 4-Vinyl Isoxazoles in the Copper-Mediated Synthesis of Pyridines, Employing DMSO as a One-Carbon Surrogate
  作者：Pravin Kumar、Manmohan Kapur

  DOI：10.1021/acs.orglett.0c01935

  日期：2020.8.7

  An efficient protocol for the synthesis of nicotinate derivatives and tetrasubstituted pyridines through a copper-mediated cleavage of isoxazoles has been developed. The highlight of the work is the observation of an unusual reactivity of 4-vinyl isoxazoles under the reaction conditions. DMSO serves as a one-carbon surrogate generating an active methylene group during the reaction to form two C–C bonds

  已经开发了一种通过铜介导的异恶唑裂解合成烟酸酯衍生物和四取代吡啶的有效方案。这项工作的重点是在反应条件下观察到4-乙烯基异恶唑具有异常的反应活性。DMSO可作为单碳替代物，在反应过程中生成两个C–C键，从而生成一个活性亚甲基。该协议为密集取代的N杂环化合物的组装提供了一种便捷的方法。
• NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER
  申请人：Guo Lei

  公开号：US20120065204A1

  公开（公告）日：2012-03-15

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R 1 to R 3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in the treatment of cancer.

  本发明提供了式（I）的化合物或其药学上可接受的盐、酯或立体异构体，其中R1至R3和X具有本文中给出的含义。本发明还涉及制备所述化合物的方法和所述化合物的用途，特别是它们作为药物的用途，更具体地说是它们作为治疗癌症的药物的用途。
• [EN] NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER<br/>[FR] NOUVEAUX N-HYDROXY-BENZAMIDES DESTINÉS AU TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012031993A1

  公开（公告）日：2012-03-15

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in the treatment of cancer.

  本发明提供了式（I）的化合物或其药用可接受的盐、酯或立体异构体，其中R1至R3和X具有本文中给出的含义。本发明还涉及制备所述化合物的方法和所述化合物的用途，特别是它们作为药物的用途，更具体地说是它们作为治疗癌症的药物的用途。

表征谱图